MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.
4 reports, 2 independent
Updated Oct 9
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.MarketBeat provides analyst recommendations comparing Rallybio and NewAmsterdam Pharma.1 source
MIaMI mentioned alongside Naarden, Netherlands; Menarini submits MAA and partners with NewAmsterdam.1 source
Keep exploring
The entities involved
-
MIaMI
Czech company
-
Netherlands
one of the four autonomous countries of the Kingdom of the Netherlands; with territories in the Caribbean
-
Menarini
Italian pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- themarketsdaily.com
- GlobeNewswireNewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib -- Filings both for the obicetrapib monotherapy and obicetrapib plus e